Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)
Keros Therapeutics (KROS) posted Preferred Stock Liabilities of $9.1 million for Q1 2020, down 54.34% on a QoQ basis from $19.9 million in Q4 2019, and down 7.94% year-over-year from $9.9 million in Q2 2019.
Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Keros Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $9.1 million for Q1 2020.
- Quarterly Preferred Stock Liabilities fell 7.94% year-over-year to $9.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $9.1 million (down 7.94% YoY) and the FY2019 annual result came in at $19.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $9.1 million for Q1 2020 at Keros Therapeutics, down from $19.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $19.9 million in Q4 2019 and bottomed at $9.1 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 9.11 Mn |
| Dec 31, 2019 | 19.94 Mn |
| Sep 30, 2019 | 9.11 Mn |
| Jun 30, 2019 | 9.89 Mn |
| Mar 31, 2019 | 9.89 Mn |